U.S. Paper and Forestry Products Stock News

In the first quarter of 2026, Allegion reported sales of US$1,033.6 million, up from US$941.9 million a year earlier, while net income declined to US$138.1 million and diluted EPS from continuing operations eased to US$1.59. The company attributed the profit pressure to margin impacts from ERP-related production issues in its international business, even as it raised full-year 2026 revenue growth guidance to 6%–8% and projected full-year EPS of US$7.95–US$8.15. Next, we will examine how...

Navan (NasdaqGS:NAVN) has secured Criteo and Schindler as new enterprise clients for its AI-powered corporate travel platform. The agreements cover multi country travel programs and use Navan’s unified system for booking, policy compliance, and traveler support. Both clients are using Navan’s tools for operational efficiency, sustainability tracking, and user satisfaction across their global workforces. For investors watching corporate travel and expense software, Navan sits at the...

Legence (NasdaqGS:LGN) reported strong quarterly results, supported by organic growth across the business. The Installation & Maintenance segment delivered major outperformance within the period. Recent acquisitions were integrated into the business, contributing to current operations. Management raised 2026 guidance, signaling higher internal expectations for future performance. Legence, listed as NasdaqGS:LGN, focuses on installation and maintenance services, an area that can be closely...

Wondering if Quanta Services at around US$750 per share still offers value, or if most of the opportunity is already priced in. The stock has returned 3.2% over the last week, 35.1% over the last month, 70.7% year to date and 130.3% over the past year, with a very large 5 year return close to 7x. These moves are drawing fresh attention to Quanta Services as investors reassess what they are willing to pay for infrastructure and capital projects exposure. Recent coverage has focused on how the...

Wondering whether FTAI Aviation stock still offers value at its current price, or if most of the opportunity is already reflected in the share price. The stock last closed at US$272.54, with returns of 9.2% over 7 days, 13.1% over 30 days, 29.6% year to date, 149.9% over 1 year, and a very large 3 year and 5 year return. Recent coverage has focused on how this rapid share price performance has put more attention on what investors are paying for each dollar of future cash flow and asset...

Wondering if Revolution Medicines at around US$142.51 is still offering value after its strong run, or if you are late to the story? This article focuses squarely on what the current price could mean for you as a shareholder. The stock has seen a 1.1% decline over the last 7 days, but that comes after strong gains of 48.0% over 30 days, 80.3% year to date, 240.0% over 1 year and a very large 3 year return of 456.2% and 5 year return of 363.6%. Recent headlines around Revolution Medicines...

Wondering if CubeSmart at US$40.25 is offering good value right now, or if the easy gains are already behind it. The stock has been relatively steady over the last year with a 0.1% return, but the 8.1% return over 30 days and 13.7% return year to date show that sentiment around the shares has shifted recently. Recent trading moves have picked up as investors reassess listed real estate and storage focused stocks more broadly, with CubeSmart part of that conversation. This has put more...

A10 Networks, Inc. has already reported first-quarter 2026 results, with revenue of US$75.0 million and net income of US$12.03 million, while its board approved a US$0.06 quarterly dividend and the company continued share repurchases under its existing buyback program. The company also reiterated its full-year 2026 outlook for revenue and earnings growth, underscoring management confidence in ongoing demand for its networking and security solutions. We’ll now examine how A10’s reaffirmed...

CVB Financial (NasdaqGS:CVBF) has completed its acquisition of Heritage Commerce Corp, creating a larger combined bank. The company has released pro forma financials for 2025 for the merged entity, giving investors a first look at the combined profile. This transaction marks a meaningful change in CVB Financial’s scale and business mix compared with its prior standalone position. CVB Financial, trading at $20.51, now reflects a business that is materially different from the one behind its...

Investors may be wondering whether RingCentral's current share price reflects its true worth, or if the recent price action has left it mispriced in either direction. The stock last closed at US$45.39, with returns of 12.9% over 7 days, 19.5% over 30 days, 64.5% year to date, 70.5% over 1 year, 58.2% over 3 years, and an 80.9% decline over 5 years. This presents a mixed picture of strong rebounds alongside longer term losses. Recent coverage has focused on RingCentral's position as a...

If you are wondering whether PTC at around US$147.65 is priced attractively, this article walks through what the current valuation signals might mean for you. The stock has seen an 8.3% move over the last 7 days and 2.6% over the past month, but is still showing a 13.2% decline year to date and a 10.4% decline over the last year, which may catch the eye of investors weighing potential opportunity against recent sentiment. Recent coverage of PTC has focused on its role as a US software...

Wondering if Scholar Rock Holding at around US$46.45 is giving you fair value or a potential opportunity? This article walks through the key numbers in plain language so you can judge for yourself. The stock has seen mixed recent returns, with a 0.3% decline over the last 7 days and a 6.9% decline over the last month, alongside gains of 8.5% year to date, 49.9% over 1 year and a very large 3 year return, plus a 63.3% gain over 5 years. These moves have come as investors weigh ongoing...

Niagen Bioscience (NAGE) is back on investors’ radar after reporting Q1 2026 results that exceeded consensus estimates, alongside the launch of its Niagen Plus telehealth platform and at-home prescription injection kits. See our latest analysis for Niagen Bioscience. Despite the upbeat Q1 report and new Niagen Plus initiatives, the stock’s recent momentum has been weak, with a 30 day share price return of a 6.26% decline and a year to date share price return of a 32.96% decline. The 3 year...

Investors may be wondering whether Evercore, at around US$331 per share, still offers value or whether most of the easy gains are already behind it. The stock has delivered a 3.1% move over the last week and 7.9% over the past month, while year to date it is at a 5.7% decline against a 54.6% return over the last year, a 225.1% return over three years, and 154.1% over five years. Recent coverage has focused on Evercore's role in major advisory mandates and its position within capital markets...

Wondering if Hercules Capital's share price really reflects what you are getting for your money? This breakdown walks through what the current market price might be missing or already pricing in. Recently, the stock closed at US$16.40, with returns of 2.2% over 7 days, 8.5% over 30 days, 4.0% over 1 year and 67.6% over both 3 and 5 years, while the year to date return sits at a 13.0% decline. These moves sit against a backdrop of ongoing interest in income focused business development...

Praxis Precision Medicines (NasdaqGS:PRAX) reported that the FDA accepted New Drug Applications for ulixacaltamide and relutrigine. The company is preparing for potential U.S. launches following these NDA acceptances. Praxis also highlighted clinical progress for elsunersen, adding to momentum across its late-stage pipeline. For readers tracking central nervous system drug developers, Praxis sits at an important point in its evolution, with ulixacaltamide and relutrigine moving into formal...

If you are wondering whether Gulfport Energy, at a last close of US$178.80, is attractively priced or if the easy gains are behind it, this article breaks down what the current share price might be implying about the stock's value. The stock has seen a 7.1% decline over the last week, a 13.9% decline over the last month, and a 13.3% decline year to date, set against a 94.6% return over the last 3 years and a 5.0% decline over the last year. Recent coverage has focused on Gulfport Energy's...

EIR Healthcare recently announced a partnership with MillerKnoll to integrate casework, furniture, and interior solutions directly into factory-built healthcare modules, aiming to deliver fully furnished, quality-checked clinics from day one. This move embeds MillerKnoll into an emerging offsite healthcare construction model that targets faster, more reliable delivery of behavioral health facilities funded by large public programs. We’ll now examine how embedding MillerKnoll’s solutions into...

For investors considering whether Cardinal Health's share price still offers value after a strong multi year run, this article explains what the current market price could be implying about the stock. The stock last closed at US$185.28, with returns of 27.2% over 1 year, 129.5% over 3 years and 270.6% over 5 years. This comes despite 7 day, 30 day and year to date returns of 3.9%, 12.9% and 9.9% declines respectively. Recent coverage around Cardinal Health has focused on its role as a major...

Aura Minerals reported record Q1 profits and record EBITDA, marking a turnaround from a loss in the prior year. The Board declared a dividend that exceeds the company's own minimum payout policy, indicating higher shareholder returns in the period. The stock, NasdaqGS:AUGO, last closed at $81.07, with very large 1 year and 3 year returns and a 62.1% gain year to date. For investors who have been tracking NasdaqGS:AUGO, this update focuses on fresh company news rather than past valuation...

Warner Music Group (WMG) opened Q1 2026 with revenue of US$1.8 billion, basic EPS of US$0.33 and net income of US$174 million, setting the tone for how investors will read the latest update against a year of compressed margins. The company has reported quarterly revenue of US$1.63 billion in Q4 2024, US$1.87 billion in Q4 2025 and US$1.84 billion in Q1 2026. Over the same period, basic EPS has ranged from US$0.08 in Q4 2024 to US$0.45 in Q1 2025 and US$0.33 in the latest quarter, leaving...

Why Suncrete (RMIX) is on investors’ radar Suncrete (RMIX) has drawn attention after a strong share price move over the past month, with the stock returning 46.5% across that period and 34.6% over the past 3 months. See our latest analysis for Suncrete. That swing in momentum, with a 46.5% 1 month share price return and 35.1% year to date share price return, sits alongside a 39.4% 1 year total shareholder return at a latest close of $15.40. If Suncrete’s recent move has you thinking about...

Sana Biotechnology (SANA) is back in focus as CEO Steve Harr prepares to deliver a business overview and company update at the BofA Securities 2026 Healthcare Conference on May 12. See our latest analysis for Sana Biotechnology. At a share price of $3.50, Sana’s 7 day share price return of 6.38% and 30 day share price return of 11.11% contrast with a year to date share price decline of 16.47%. The 1 year total shareholder return of 93.37% sits against weaker 3 and 5 year total shareholder...

If you are wondering whether Asana’s current share price reflects its true worth, this breakdown will help you weigh what the market is pricing in against what the fundamentals suggest. Asana’s stock last closed at US$7.05, with a 7 day return of 11.6% and a 30 day return of 13.7%. However, the year to date return of negative 45.6% and 1 year return of negative 59.1% highlight that many holders have faced a tough ride. Those recent moves sit against a backdrop of ongoing coverage around...